Jeff Martin
Stock Analyst at Roth MKM
(4.26)
# 260
Out of 4,818 analysts
63
Total ratings
53.33%
Success rate
13.94%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $3.53 | +154.96% | 1 | Mar 20, 2025 | |
| NVEE NV5 Global | Maintains: Buy | $27 → $28 | $15.75 | +77.78% | 7 | Feb 21, 2025 | |
| OSIS OSI Systems | Maintains: Buy | $178 → $224 | $196.84 | +13.80% | 15 | Jan 24, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $40.37 | +11.47% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $25.52 | +17.55% | 6 | Nov 5, 2024 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $47 → $43 | $21.88 | +96.53% | 5 | Aug 8, 2024 | |
| FC Franklin Covey Co. | Reiterates: Buy | $50 | $20.22 | +147.28% | 7 | Jun 27, 2024 | |
| PERI Perion Network | Downgrades: Neutral | $35 → $13 | $8.62 | +50.81% | 7 | Apr 9, 2024 | |
| NSP Insperity | Maintains: Buy | $144 → $147 | $78.96 | +86.17% | 8 | Apr 27, 2023 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $1.61 | +357,663.98% | 2 | Nov 15, 2017 |
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.53
Upside: +154.96%
NV5 Global
Feb 21, 2025
Maintains: Buy
Price Target: $27 → $28
Current: $15.75
Upside: +77.78%
OSI Systems
Jan 24, 2025
Maintains: Buy
Price Target: $178 → $224
Current: $196.84
Upside: +13.80%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $40.37
Upside: +11.47%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $25.52
Upside: +17.55%
Bowman Consulting Group
Aug 8, 2024
Maintains: Buy
Price Target: $47 → $43
Current: $21.88
Upside: +96.53%
Franklin Covey Co.
Jun 27, 2024
Reiterates: Buy
Price Target: $50
Current: $20.22
Upside: +147.28%
Perion Network
Apr 9, 2024
Downgrades: Neutral
Price Target: $35 → $13
Current: $8.62
Upside: +50.81%
Insperity
Apr 27, 2023
Maintains: Buy
Price Target: $144 → $147
Current: $78.96
Upside: +86.17%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $1.61
Upside: +357,663.98%